ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The protocols including ciclosporin A （CsA）+methotrexate (MTX) +mycophenolate Mofetil(MMF)
have been widely used for graft-versus-host disease (GVHD) prophylaxis in allogeneic
hematopoietic stem cell transplantation from HLA-matched sibling donor (MSD). Nevertheless,
severe chronic graft-versus-host disease (cGVHD) remains an obstacle for MSD HSCT. A growing
body of studies have suggested antithymocyte globulin (ATG) could reduce the incidence of
cGVHD. This study is aim to evaluate the efficacy of a protocol that includes CsA, MTX, MMF
and ATG in recipients of MSD HSCT.